Krystal Biotech, Inc.
Krystal Biotech, Inc. Fundamental Analysis
Krystal Biotech, Inc. (KRYS) shows moderate financial fundamentals with a PE ratio of 38.40, profit margin of 52.64%, and ROE of 18.69%. The company generates $0.4B in annual revenue with strong year-over-year growth of 33.94%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 93.4/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.
Fundamental Health Score
We analyze KRYS's fundamental strength across five key dimensions:
Efficiency Score
ExcellentKRYS demonstrates superior asset utilization.
Valuation Score
WeakKRYS trades at a premium to fair value.
Growth Score
ModerateKRYS shows steady but slowing expansion.
Financial Health Score
ExcellentKRYS maintains a strong and stable balance sheet.
Profitability Score
ExcellentKRYS achieves industry-leading margins.
Key Financial Metrics
Is KRYS Expensive or Cheap?
P/E Ratio
KRYS trades at 38.40 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, KRYS's PEG of 13.93 indicates potential overvaluation.
Price to Book
The market values Krystal Biotech, Inc. at 6.45 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 49.85 times EBITDA. This signals the market has high growth expectations.
How Well Does KRYS Make Money?
Net Profit Margin
For every $100 in sales, Krystal Biotech, Inc. keeps $52.64 as profit after all expenses.
Operating Margin
Core operations generate 41.45 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $18.69 in profit for every $100 of shareholder equity.
ROA
Krystal Biotech, Inc. generates $15.36 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Krystal Biotech, Inc. generates strong operating cash flow of $201.24M, reflecting robust business health.
Free Cash Flow
Krystal Biotech, Inc. generates strong free cash flow of $189.26M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $6.53 in free cash annually.
FCF Yield
KRYS converts 2.38% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
38.40
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
13.93
vs 25 benchmark
P/B Ratio
Price to book value ratio
6.45
vs 25 benchmark
P/S Ratio
Price to sales ratio
20.25
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.008
vs 25 benchmark
Current Ratio
Current assets to current liabilities
9.95
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.19
vs 25 benchmark
ROA
Return on assets percentage
0.15
vs 25 benchmark
ROCE
Return on capital employed
0.13
vs 25 benchmark
How KRYS Stacks Against Its Sector Peers
| Metric | KRYS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 38.40 | 29.28 | Worse (Expensive) |
| ROE | 18.69% | 820.00% | Weak |
| Net Margin | 52.64% | -19731.00% (disorted) | Strong |
| Debt/Equity | 0.01 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 9.95 | 4.69 | Strong Liquidity |
| ROA | 15.36% | -17993.00% (disorted) | Strong |
KRYS outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Krystal Biotech, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
0.00%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
513.32%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
599.86%
Industry Style: Defensive, Growth, Innovation
High Growth